

## BIOTECON Therapeutics

[View the current BIOTECON Therapeutics Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/19899-BIOTECON+Therapeutics.html)

(<http://www.bioportfolio.com/biocorporate/19899-BIOTECON+Therapeutics.html>)

### Contact Details:

Hermannswerder Haus 17  
Potsdam

Tel: (+49-331) 23 00 - 100

Fax: (+49-331) 23 00 - 199

Email: [biatecon@biatecon.com](mailto:biatecon@biatecon.com)

14473

Germany

BIOTECON Therapeutics is engaged in the development of pharmaceutical preparations based on the various serotypes of botulinum toxin. These toxins, produced by the bacterium *Clostridium botulinum*, are the cause of botulism, which is acquired in most cases by food poisoning and leads to a potentially fatal flaccid paralysis of striated muscles. During the last decade botulinum toxins have attracted increasing interest as potent pharmaceuticals for the treatment of dystonias, spasms, hyperhydrosis and several other disorders connected with muscle hyperfunction.

### Press Releases on BIOTECON Therapeutics:

[Anesiva Announces](#)

[Prospective Board](#)

[Members To Be](#)

[Appointed Upon](#)

[Successful Completion](#)

[of Proposed Merger](#)

23rd November, 2009 Anesiva, Inc.

*SOUTH SAN FRANCISCO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that Dr. Ted W. Love and Dr. David C. U&apos;Prichard have agreed to join the Anesiva board*

*CARY, N.C., Nov. 20*

*/PRNewswire-FirstCall/ --*

*Cornerstone Therapeutics Inc.*

*(Nasdaq: CRTX), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products*

[Cornerstone](#)

[Therapeutics Provides a](#)

[Response to FDA](#)

[Warning Letter on](#)

[Deconsal](#)

20th November, 2009

Cornerstone  
Therapeutics Inc.

[Reportlinker Adds Global Self Monitoring Blood Glucose Market \(SMBG\): Increasing Adoption to Drive Growth](#)

20th November, 2009 Reportlinker

NEW YORK, Nov. 20 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Global Self Monitoring Blood Glucose Market (SMBG): Increasing Adoption to

[Cell Therapeutics Wins Federal Appeal to Pursue \\$22.8 Million Claim Against The Lash Group](#)

20th November, 2009 Cell Therapeutics, Inc.

SEATTLE, Nov. 20 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the Ninth Circuit Court of Appeals reversed a U.S. District Court order and ruled

[Monogram Energy, Inc. Acquires Triad Therapeutics, Inc.](#)

19th November, 2009 Monogram Energy, Inc.

FAIRFIELD, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Monogram Energy, Inc. ("Monogram") (Pink Sheets: MGRN) announced today that it had completed the acquisition of Triad Therapeutics, Inc. (

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

